J-HOTATE-ASSOCIATION
15.4.2024 13:01:34 CEST | Business Wire | Press release
Japan Scallop Export Promotion Association (“J-HOTATE Association”), which aims to expand the export of Japanese scallops, will be presenting the Japanese scallops to European markets at the Seafood Expo Global, which will be held in Barcelona, Spain, from April 23rd to April 25th, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415920416/en/
Japanese Scallop - A Sustainable Gastronomic Delight (Photo: Business Wire)
Japanese scallops (we say HOTATE [Hoh-Tah-Teh]) are highly accredited for their flavor, size, and quality. Fresh scallops can be enjoyed year-round under environmentally friendly farming/harvesting methods and the advanced technology to maintain freshness—both of which are unique to Japan. Especially in Hokkaido, Aomori, Iwate, and Miyagi where scallops are produced, local ocean currents provide highly rich nutrients, boasting one of the world’s largest landings of scallops.
Scallops are also known as a healthy seafood. They are rich in nutrients such as vitamin B1, which is effective in alleviating fatigue and improving concentration, and taurine, which is known to improve heart and liver function and help to prevent diabetes. Furthermore, scallops are high in protein and low in calories, making them fit to be a superfood.
Japan is unique to other parts of the world in that the proximity of fishing grounds and ports allows for scallops to be processed and distributed immediately after they are caught, and it has become a common custom in Japan for scallops to be eaten raw. Today, scallops are rapidly frozen right after landing, allowing overseas distribution while maintaining quality.
Exports of Japanese scallop products from Japan to other countries reached a record high of 94.5 billion JPY (approx. 128,000 tons in weight) in 2022, surpassing double its value (over 1.6 times in weight) of that of 2020, when markets stalled due to COVID-19.
Export Data of Japanese Scallops (worldwide) |
|||||||||
(Units: tons/millions JPY/kg) |
|||||||||
2020 |
2021 |
2022 |
|||||||
Weight |
Amount |
PPU |
Weight |
Amount |
PPU |
Weight |
Amount |
PPU |
|
Raw |
13,990 |
5,090 |
364 |
19,597 |
8,173 |
417 |
16,356 |
9,512 |
582 |
Dried |
1,167 |
7,154 |
6,128 |
994 |
5,967 |
6,001 |
454 |
3,914 |
8,628 |
Frozen |
63,556 |
26,216 |
412 |
96,392 |
55,877 |
580 |
111,392 |
81,099 |
728 |
Total |
78,713 |
38,460 |
489 |
116,983 |
70,018 |
599 |
128,203 |
94,526 |
737 |
Source: J-HOTATE Association |
|||||||||
The association has participated in the Seafood Expo in Boston and Singapore and received positive reactions from local firms of North America and Asian countries interested in connecting with Japanese scallop suppliers.
Our goals with the first exhibition in Europe are to increase the export of Japanese scallops and promote the traditional Japanese "eating raw" culture to taste the fullness of scallops' rich nutritional value. The booth will include a business meeting space, introduction of Japanese scallop products and production areas, as well as showing samples of scallops at regular and frozen temperatures, and providing tasting samples of scallops, shipped straight from Japan in Sushi/Sashimi and fried styles.
[Exhibit Information]
Event: Seafood Expo Global (https://www.seafoodexpo.com/global/)
Booth Number: 1F701 (Hall 1)
Date: April 23–April 25, 2024
Venue: FIRA BARCELONA GRAN VIA VENUE
About Japan Scallop Export Promotion Association (“J-HOTATE Association”)
The Japan Scallop Export Promotion Association (J-HOTATE Association) was incorporated in October 2023, with the aim of expanding exports of Japanese scallop products with high quality and healthy flavours through sustainable cultivation. The J-HOTATE Association is currently composed of seventy-four members, including producers (fishery cooperative associations), processors and fisheries-related distributors of Japan and traders. https://j-hotate.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415920416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
